Lupi A, Orsolon P, Cerisara D, Deantoni Migliorati G, Vianello Dri A
Unità Operativa di Medicina Nucleare, Ospedale S. Bortolo, Vicenza, Italy.
Minerva Endocrinol. 2002 Mar;27(1):53-7.
It seems somewhat difficult to exactly define the real number of case reports concerning the association of hyperfunctioning thyroid node and carcinoma; the overall incidence of this condition seems, however, to be very rare. Different inclusion criteria are probably a fairly relevant cause of variability in the number of cases reported during the years. A basic classification scheme, as the one here reported, may be of help in characterizing the different possible conditions: 1. the coexistence of carcinoma and focally hyperfunctioning tissue in the same gland but at different locations (not uncommon); 2. the presence of such a large tumour mass that it can compete with normal tissue for tracer uptake, despite being hormonogenetically uneffective in itself; 3. the carcinoma located in the hyperfunctioning adenoma; 4. the real hyperfunctioning carcinoma, where coincidence between hyperfunctioning tissue and malignancy is complete (very rare). Two cases are reported here, respectively belonging to the third and fourth of these categories (the most challenging from a diagnostic point of view). The matter is intrinsically poor from a statistical standpoint: it is therefore difficult to draw definitive conclusions on the subject in operative terms. It is however felt that the systematic evaluation of oncological risk in thyroid nodes, occasionally recommended in the literature, may be cumbersome and not necessarily cost-effective.
准确界定有关甲状腺功能亢进结节与癌关联的病例报告实际数量似乎有些困难;然而,这种情况的总体发病率似乎非常罕见。不同的纳入标准可能是多年来报告病例数量存在差异的一个相当重要的原因。像这里所报告的这种基本分类方案,可能有助于描述不同的可能情况:1. 癌与同一腺体中不同部位的局灶性功能亢进组织并存(并不罕见);2. 存在如此大的肿瘤块,以至于尽管其本身在激素生成方面无作用,但仍能与正常组织竞争摄取示踪剂;3. 癌位于功能亢进性腺瘤内;4. 真正的功能亢进性癌,即功能亢进组织与恶性肿瘤完全重合(非常罕见)。这里报告了两例,分别属于上述类别中的第三类和第四类(从诊断角度来看最具挑战性)。从统计学角度来看,这个问题本质上数据不足:因此很难从操作层面就该主题得出明确结论。然而,有人认为,文献中偶尔推荐的对甲状腺结节肿瘤风险进行系统评估可能麻烦且不一定具有成本效益。